Loading...
Market
Story
Valar Labs Raises $22M Series A for AI-Powered Bladder Cancer Care Tool
May 30, 2024, 04:10 PM
Valar Labs has announced the successful completion of a $22 million Series A funding round, co-led by DCVC and a16z, with participation from Pear VC. The biotech startup has developed an AI-powered diagnostic tool, Vesta, which predicts treatment responses for bladder cancer patients. This tool, based on computational histology, aims to reduce uncertainty in cancer treatment decisions and is already in commercial use for bladder cancer. Valar Labs plans to expand its application to other types of cancer. The technology has been highlighted in a Nature story, and the company aims to translate this tech to clinical settings, potentially saving precious time for patients. There are roughly 2 million new cancer diagnoses annually in the US alone.
View original story
Similar markets
Less than $10 million • 33%
$10 million to $20 million • 33%
More than $20 million • 34%
Pharmaceutical Company • 25%
Cancer Research Institution • 25%
University • 25%
Other Healthcare Provider • 25%
Less than $200 million • 25%
$200 million to $300 million • 25%
$300 million to $400 million • 25%
More than $400 million • 25%
Less than $50 million • 25%
$50 million to $100 million • 25%
$100 million to $150 million • 25%
More than $150 million • 25%
Under $10 million • 33%
$10-$50 million • 33%
Over $50 million • 33%
Under $1 billion • 25%
$1 billion - $2 billion • 25%
$2 billion - $3 billion • 25%
Over $3 billion • 25%
North America • 25%
Europe • 25%
Asia • 25%
Other • 25%
Less than $500 million • 25%
$500 million - $1 billion • 25%
$1 billion - $1.5 billion • 25%
More than $1.5 billion • 25%
Below $1 billion • 33%
$1-$5 billion • 33%
Above $5 billion • 33%
Less than $10M • 25%
$10M to $20M • 25%
$20M to $30M • 25%
More than $30M • 25%